- Home
- OPK
OPK
OPKO Health Inc.
as 07-26-2024 4:00pm EST
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a world supply-chain operation and holding company in Ireland. It also owns a specialty active pharmaceutical ingredients manufacturer in Israel. It operates in two segments Diagnostics and Pharmaceuticals.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | MIAMI |
| Market Cap: | 1.1B | IPO Year: | 1995 |
| Target Price: | $2.50 | AVG Volume (30 days): | 3.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.35 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.85 - $2.17 | Next Earning Date: | 08-05-2024 |
| Revenue: | $799,603,000 | Revenue Growth: | -12.38% |
| Revenue Growth (this year): | -16.84% | Revenue Growth (next year): | 4.93% |
Stock Insider Trading Activity of OPKO Health Inc. (OPK)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| OPKO HEALTH, INC. | OPK | 10% Owner | Jul 5 '24 | Sell | $28.24 | 36,118 | $1,020,015.66 | 3,433,403 | SEC Form 4 |
| OPKO HEALTH, INC. | OPK | 10% Owner | Jul 1 '24 | Sell | $28.23 | 14,082 | $397,491.21 | 3,469,521 | SEC Form 4 |
| OPKO HEALTH, INC. | OPK | 10% Owner | Jul 1 '24 | Sell | $29.12 | 25,000 | $728,095.00 | 3,483,603 | SEC Form 4 |
| OPKO HEALTH, INC. | OPK | 10% Owner | Jul 1 '24 | Sell | $26.63 | 50,000 | $1,331,700.00 | 3,508,603 | SEC Form 4 |
| FROST PHILLIP MD ET AL | OPK | CEO & Chairman | May 23 '24 | Buy | $1.27 | 99,230 | $125,962.56 | 211,231,452 | SEC Form 4 |
| FROST PHILLIP MD ET AL | OPK | CEO & Chairman | May 23 '24 | Buy | $1.27 | 770 | $974.05 | 211,232,222 | SEC Form 4 |
| FROST PHILLIP MD ET AL | OPK | CEO & Chairman | May 17 '24 | Buy | $1.29 | 163,997 | $211,195.34 | 211,132,222 | SEC Form 4 |
| FROST PHILLIP MD ET AL | OPK | CEO & Chairman | Mar 18 '24 | Buy | $0.87 | 500,000 | $437,100.00 | 210,968,225 | SEC Form 4 |
| FROST PHILLIP MD ET AL | OPK | CEO & Chairman | Mar 14 '24 | Buy | $0.89 | 500,000 | $444,300.00 | 210,468,225 | SEC Form 4 |
| FROST PHILLIP MD ET AL | OPK | CEO & Chairman | Mar 13 '24 | Buy | $0.93 | 500,000 | $463,750.00 | 209,968,225 | SEC Form 4 |
| FROST PHILLIP MD ET AL | OPK | CEO & Chairman | Mar 12 '24 | Buy | $0.93 | 600,000 | $559,380.00 | 209,468,225 | SEC Form 4 |
| FROST PHILLIP MD ET AL | OPK | CEO & Chairman | Feb 28 '24 | Buy | $0.99 | 500,000 | $496,150.00 | 208,868,225 | SEC Form 4 |
| FROST PHILLIP MD ET AL | OPK | CEO & Chairman | Feb 21 '24 | Buy | $0.99 | 1,000,000 | $991,700.00 | 208,368,225 | SEC Form 4 |
| FROST PHILLIP MD ET AL | OPK | CEO & Chairman | Feb 7 '24 | Buy | $0.98 | 1,500,000 | $1,462,800.00 | 207,368,225 | SEC Form 4 |
| KRASNO RICHARD M | OPK | Director | Jan 29 '24 | Buy | $0.99 | 30,000 | $29,838.00 | 103,333 | SEC Form 4 |
| FROST PHILLIP MD ET AL | OPK | CEO & Chairman | Jan 19 '24 | Buy | $0.98 | 500,000 | $488,650.00 | 205,868,225 | SEC Form 4 |
| FROST PHILLIP MD ET AL | OPK | CEO & Chairman | Jan 18 '24 | Buy | $0.97 | 400,000 | $386,200.00 | 205,368,225 | SEC Form 4 |
| HSIAO JANE PH D | OPK | Vice Chairman & CTO | Jan 17 '24 | Buy | $0.95 | 150,000 | $142,500.00 | 27,999,880 | SEC Form 4 |
| FROST PHILLIP MD ET AL | OPK | CEO & Chairman | Jan 16 '24 | Buy | $0.95 | 1,000,000 | $954,300.00 | 204,968,225 | SEC Form 4 |
| FROST PHILLIP MD ET AL | OPK | CEO & Chairman | Jan 11 '24 | Buy | $0.94 | 511,531 | $480,378.76 | 203,968,225 | SEC Form 4 |
| Nabel Gary J. | OPK | Chief Innovation Officer | Jan 8 '24 | Buy | $0.93 | 108,695 | $100,542.88 | 351,442 | SEC Form 4 |
| Nabel Gary J. | OPK | Chief Innovation Officer | Jan 8 '24 | Buy | $0.92 | 500 | $458.90 | 500 | SEC Form 4 |
| Nabel Gary J. | OPK | Chief Innovation Officer | Jan 8 '24 | Buy | $0.93 | 106,989 | $99,424.88 | 107,489 | SEC Form 4 |
| Zerhouni Elias A. | OPK | Vice Chairman and President | Jan 5 '24 | Buy | $0.87 | 17,000 | $14,790.00 | 19,794,514 | SEC Form 4 |
| Zerhouni Elias A. | OPK | Vice Chairman and President | Jan 5 '24 | Buy | $0.91 | 33,300 | $30,303.00 | 19,827,814 | SEC Form 4 |
Latest OPKO Health Inc. News
OPK Breaking Stock News: Dive into OPK Ticker-Specific Updates for Smart Investing
MT Newswires
8 days ago
Piper Sandler Adjusts OPKO Health Price Target to $3 From $5, Maintains Overweight Rating
MT Newswires
8 days ago
Piper Sandler Adjusts Price Target on OPKO Health to $3 From $5, Maintains Overweight Rating
MT Newswires
8 days ago
Sector Update: Health Care Stocks Edge Lower Premarket Thursday
MT Newswires
8 days ago
Sector Update: Health Care
MT Newswires
8 days ago
OPKO Health Board Approves $100 Million Share-Buyback Program
GlobeNewswire
9 days ago
OPKO Health Announces $100 Million Share Repurchase Program
MT Newswires
9 days ago
OPKO Health Raises $250 Million Non-Dillutive Capital Via Note Issue
GlobeNewswire
9 days ago
OPKO Health and HealthCare Royalty Enter into $250 Million Note Purchase Agreement Secured by NGENLA’s Profit Share Payments
Compare OPK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OPK OPKO Health Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.